Pfizer's ELREXFIO Shows Median Overall Survival Of More Than Two Years In Phase 2 MagnetisMM-3 Study
Portfolio Pulse from Benzinga Newsdesk
Pfizer Inc. (NYSE:PFE) announced that its drug ELREXFIO showed a median overall survival of 24.6 months in a Phase 2 study for patients with relapsed or refractory multiple myeloma.
June 14, 2024 | 7:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's ELREXFIO demonstrated a median overall survival of 24.6 months in a Phase 2 study for relapsed or refractory multiple myeloma, indicating strong efficacy.
The positive results from the Phase 2 study of ELREXFIO are likely to boost investor confidence in Pfizer's oncology pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100